Locetar

Quick links to important sections

Locetar

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Locetar

Defining Locetar and its Morpholine Classification

Locetar is an antifungal agent belonging to the morpholine class, with amorolfine hydrochloride as its sole active ingredient. It is a synthetic derivative designed for fungal issues, specifically onychomycosis (fungal infection of the nails). This classification within the morpholine group distinguishes it from traditional azoles or allylamines through its chemical structure and dual enzymatic inhibition mechanism, which is intended for broad-spectrum activity. This makes the medicine a targeted option for addressing the organisms responsible for nail infections.

The drug is formally classified under the Anatomical Therapeutic Chemical (ATC) code D01AE16, designating it as a topical antifungal. This classification establishes the drug’s primary purpose and pharmacological identity.

Composition and Specialized Topical Delivery

The medicine is supplied as a specialized dosage form known as a medicated nail lacquer, intended for topical administration directly onto the affected nail. This preparation is a single active ingredient product, combining amorolfine hydrochloride with an organic solvent base that enables the formation of a durable film upon drying. This lacquer formulation is a key feature, enabling persistent, local treatment and is specifically engineered for action where the infection resides.

Mechanism Principle: Disrupting Fungal Cell Integrity

Amorolfine's effectiveness stems from its ability to disrupt the structure of the fungal cell membrane by blocking the creation of key components. It exerts both fungicidal (fungus-killing) and fungistatic (growth-inhibiting) effects. This approach prevents the fungus from maintaining its necessary structure, thereby stopping the infection's progression and allowing the natural healing process to commence.

What side effects are possible with Locetar?

Possible side effects and safety information

The adverse reactions associated with Locetar (Amorolfine) medicated nail lacquer are primarily localized to the application area, reflecting the medicine's very low systemic absorption following topical use. The official safety information structures the potential risks based on regulatory frequency classifications and the affected organ systems.


Frequency-Classified Adverse Reactions

The majority of reported effects fall into the less frequent categories as defined by regulatory documents:

  • Rare (affecting up to 1 in 1,000 people): Nail disorders, including nail discolouration, onychorrhexis (brittle nails), and onychoclasis (broken nails). Note that these effects may be difficult to distinguish from the symptoms of the underlying fungal infection.
  • Very Rare (affecting less than 1 in 10,000 people): Skin burning sensation.
  • Not Known (Frequency cannot be estimated from available data): Local reactions such as erythema (redness), pruritus (itching), contact dermatitis, urticaria (hives), and blister formation, which are reported in post-marketing experience.

Systemic and Population Safety Notes

Adverse reactions are predominantly classified under Skin and Subcutaneous Tissue Disorders. However, the regulatory documentation includes reports of Systemic Hypersensitivity (allergic reaction) under Immune System Disorders, which is a potentially serious reaction of unknown frequency. Symptoms may include swelling of the face or throat, respiratory issues, or a severe skin rash.

Official safety statements advise against use in specific populations due to a lack of adequate clinical experience and data. Locetar is not recommended for use in children and adolescents under 18 years of age or during pregnancy and breastfeeding.

Overdose and Emergency Response

The official regulatory profile for Locetar (Amorolfine 5% Medicated Nail Lacquer) confirms that overdose risk is structured around its topical route of administration. Because this is a localized treatment, no systemic signs of overdose are expected from the intended application to the nail. This is due to the drug's very low level of absorption into the body, a factor confirmed within official prescribing information.

The regulatory focus is confined entirely to a single exposure scenario: accidental oral ingestion of the nail lacquer. This circumstance represents the only documented risk that mandates immediate medical intervention. Should accidental swallowing occur, the regulator instructs that medical help must be sought immediately by contacting a doctor, a pharmacist, or the nearest emergency department.

Management of accidental ingestion involves taking appropriate symptomatic measures as determined by a healthcare professional. Furthermore, regulatory guidance specifically suggests that a procedure for gastric emptying may be considered following this exposure. The official labeling does not specify any known antidote for Amorolfine overdose.

Therapeutic Uses of Locetar

What Locetar Treats: Main Uses and Benefits

Locetar is commonly used to help with fungal infections affecting the nails (onychomycosis), which are generally caused by dermatophytes, yeasts, and molds. The treatment is commonly applied to address localized infections, which may assist with addressing the underlying cause of the symptomatic discomfort. It is often utilized for mild to moderate forms of this condition. The treatment is relevant for easing symptoms by supporting the therapeutic area of fungal elimination, and supports the process of nail recovery.


The medication is commonly used for managing groups of symptoms that cause aesthetic and structural changes in the nail, including pronounced symptoms of nail discoloration, thickening, splitting, and separation (onycholysis). The treatment may contribute to improved comfort during symptomatic periods by assisting with maintaining the functional stability and appearance of the nail. This supports patients during episodes of heightened discomfort by easing the overall symptom load of physical manifestations.

It is considered a relevant localized topical option, generally used as a stand-alone treatment (monotherapy) for smaller infections. It is also applicable in clinical settings that involve acute or disruptive symptom patterns where additional symptomatic support is needed.


Condition Categories: Structural Nail Change

Locetar is used for managing conditions that present with visible nail issues, is applied in addressing nail thickening and discoloration, and is a therapeutic option relevant for adults requiring long-term, localized management of fungal nail disease.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Locetar (Amorolfine 5% Nail Lacquer)

The eligibility for using Locetar is strictly defined by regulatory documents, focusing on age, reproductive status, and sensitivity to the medicine’s components. Locetar is contraindicated in patients with a known hypersensitivity to the active substance, amorolfine, or to any of the excipients in the nail lacquer formulation.

Age-Group Eligibility

Age Group Eligibility Status (Regulatory Wording)
Adults (18+ years) Approved for use under standard labeled conditions.
Children and Adolescents Use is not recommended due to a lack of clinical experience in these age groups.

Conditional Use and Restrictions

Use of Locetar is not recommended during pregnancy and lactation unless deemed clearly necessary. Additionally, the official label advises that use requires caution in patients with underlying health issues such as diabetes mellitus, peripheral circulatory disorders, or immunosuppression.

What should I know about interactions with other medicines?

The official regulatory profile for Locetar (amorolfine nail lacquer) is defined by its topical application, which results in minimal systemic absorption of the active ingredient. Consequently, regulatory documents consistently state that no formal drug–drug interaction studies have been performed and that there are no known interactions with other systemic medicines.

The interaction constraints listed in official documentation relate primarily to administration and the physical properties of the nail lacquer film:

Interaction-Related Restriction Official Regulatory Statement
Interacting Products Cosmetic nail varnish and artificial nails must be avoided during the treatment period.
Timing Separation Rule If cosmetic nail lacquer is used, a minimum interval of 10 minutes must be respected after the application of Locetar.
Organic Solvents When handling organic solvents (e.g., thinners, white spirit), impermeable gloves must be worn to prevent the removal of the medicated lacquer layer.
Flammability The product contains ethanol and is classified as a flammable substance; it must be kept away from heat, open flames, and lit cigarettes until completely dry.

These constraints establish that the risk of systemic pharmacokinetic or pharmacodynamic interactions with other medicines is not considered clinically relevant by regulatory authorities. The focus is instead on maintaining the integrity and efficacy of the medicated layer on the nail.

Mechanism of Action

Locetar's mechanism of action, mediated by amorolfine, is strictly targeted at the fungal cell, utilizing a dual-inhibition mechanism that results in both fungicidal (killing) and fungistatic (growth-inhibiting) effects. This process operates through two key mechanistic domains.

Molecular Inhibition of Ergosterol Synthesis

The drug engages mechanisms that block the Ergosterol biosynthesis pathway, which is necessary for maintaining fungal cell membrane structure. This occurs through the simultaneous, non-competitive inhibition of two critical fungal enzymes: mathbfDelta 14-sterol reductase and mathbfDelta 7-mathbfDelta 8-isomerase. By targeting these distinct molecular steps, the drug halts the production of necessary Ergosterol and causes the accumulation of the toxic, non-functional intermediate Ignosterol.

Fungal Cell Membrane Destruction

The combination of Ergosterol depletion and Ignosterol accumulation results in profound alterations to the fungal cell membrane. This structural compromise leads to a fatal loss of membrane fluidity and an increase in permeability. This effect initiates a cellular cascade culminating in cell lysis—the irreversible destruction and death of the fungal organism—which is the physiological consequence of eliminating the fungal organism at the cellular level.

Dosage and Administration Information

Administration Method

Locetar is a medicated nail lacquer intended for topical application to affected fingernails or toenails. The application process involves preparing the nail surface to ensure the lacquer can be applied effectively.

Preparation of the Nail

Before the lacquer is applied, the affected areas of the nail, particularly the surface, should be filed down as thoroughly as possible. Following filing, the surface must be cleansed and degreased. This preparation is typically performed using a cleansing pad or a cotton swab soaked in a nail polish remover or alcohol.

Application of the Lacquer

The lacquer is applied evenly over the entire surface of the affected nail. It is necessary to allow the lacquer to dry completely after application. Once the lacquer has dried, it forms a film on the nail.

Maintenance Between Applications

Prior to each subsequent application, any remaining lacquer from the previous use must be removed. This is done by filing the nail surface again and cleansing it to ensure the new layer of lacquer can be applied to a clean surface. The filing and cleansing process should be repeated for every affected nail throughout the duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Locetar

Locetar (amorolfine) was studied for its use as a topical treatment for fungal infections of the nail (onychomycosis). Research has focused on understanding the patterns observed in the studies regarding the measured change in the visible appearance of the nail and the measurement of fungal presence. The available evidence, primarily derived from clinical trials and systematic reviews, provides context but not individual predictions regarding treatment outcomes.

Evidence for Use in Fungal Infections of the Nail (Onychomycosis)

Research has involved Randomized Controlled Trials (RCTs) to examine Locetar when applied in studies examining fungal nail infections. These studies specifically were evaluated in adults who have mild to moderate forms of the condition. The main measurements researchers used included the mycological cure rate (confirming the fungus is no longer present) and the clinical cure rate (based on the appearance of a visually near-normal nail).

Comparing Study Designs and Treatment Approaches

Locetar was evaluated in trials that compared its application to a placebo (a lacquer with no active medicine) and was explored in comparison with other topical antifungal products. Some trials were studied for its use in a combination with oral antifungal tablets. Studies reported that the measurements for outcomes were distinct when the lacquer was used alone compared to when it was evaluated with an oral treatment, and comparative evidence is lacking for some direct head-to-head comparisons.

Long-Term Studies and Follow-Up

Due to the slow growth of the nail, treatment and follow-up periods in the research extended for 6 to 9 months for the treatment phase itself, and up to 12 or 18 months for observation. Trials monitored patients to understand the persistence of the observed outcomes and patterns of recurrence. However, long-term effects are not fully established beyond the typical follow-up periods.

What is Still Uncertain About Locetar Studies

Data for certain groups remain insufficient, particularly for complex cases or specific patient groups like children. Subgroup findings are uncertain because the sample sizes were modest for certain trials. Additionally, the lack of a fully standardized definition of "cure" contributes to variability in the reported measurements between studies.

Key Studies & References

  1. Summary of Product Characteristics (Loceryl 5% w/v Medicated Nail Lacquer) - Regulatory Scope and Indications
  2. Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials (Evidence on Monotherapy vs. Combination)

Frequently Asked Questions (FAQ)

Common questions about Locetar (FAQ)

Q: Are there any common misuses of Locetar that people should avoid?

A: Regulatory documents specify that contact with the eyes, ears, and mucous membranes is to be avoided. The official product information also advises avoiding the use of cosmetic nail polish or artificial nails during treatment. Further, using impermeable gloves is specified when handling organic solvents like paint thinners, as this helps protect the medicated film on the nail.

Q: What is the difference between Locetar and other common nail treatments?

A: Locetar belongs to the morpholine class of topical antifungal agents, and its active ingredient is amorolfine. This classification refers to its unique dual-action mechanism, which works by altering the fungal cell membrane. This structural compromise is essential to fungal survival and growth, which differentiates it chemically from other major classes of topical antifungal drugs.

Q: Are there different strengths of Locetar lacquer, and what do the numbers mean?

A: According to the official product information, Locetar is available as a 5% w/v medicated nail lacquer. The '5% w/v' indicates the concentration of the active ingredient, amorolfine, within the final product formulation.

Q: Why do some people report Locetar not working for them?

A: Official documents indicate that the medicine is authorized for mild cases of fungal nail infection. If the infection is widespread or severe, topical treatment alone may not align with the authorized use. Lack of success may also be linked to discontinuing treatment too early, as the course must last until the nail is fully regenerated.

Q: How does Locetar compare to prescription oral medications for nail fungus?

A: Locetar is a topical medicine with very low systemic absorption, meaning the active ingredient primarily acts locally on the nail plate. In contrast, prescription oral medications work systemically throughout the body. Combination therapy, which involves both topical and oral treatments, has been studied in clinical trials.

Q: What is the risk of the fungal infection returning after stopping Locetar?

A: Official guidelines emphasize that the full course of treatment must be completed to ensure the nail is entirely regenerated and definitively cured. This is viewed as essential to reduce the risk of the fungal infection returning after treatment stops. Clinical studies have included observing patterns of recurrence and have explored the possibility of using a reduced frequency of application following the primary treatment phase.

Q: If Locetar works, how does the new, healthy nail look?

A: According to the regulatory objective, treatment is considered complete when the infected areas are definitively cured and the nail is fully regenerated. The clinical cure rate, which is a key measurement in studies, is based on the appearance of a visually near-normal, clear nail.

Q: Why is alcohol used in the product, and what is its purpose?

A: Official product information states that the lacquer formulation contains ethanol anhydrous (alcohol) as an excipient. The excipients are necessary to create the specialized nail lacquer base. This base allows the amorolfine to penetrate the nail and form a durable, medicated film that adheres to the nail surface.

Q: What are the reported major side effects that require immediate medical attention?

A: The most serious reported reaction noted in official documents is a risk of systemic hypersensitivity, which is a severe allergic reaction. Although rare, if symptoms such as swelling of the face, throat, or lips, difficulty breathing, or a severe skin rash are experienced, medical attention should be sought promptly.

Q: Is Locetar safe for people who have sensitive skin or eczema?

A: Official safety information indicates that localized skin reactions at or around the application site, such as redness (erythema), itching (pruritus), and contact dermatitis, have been reported. The risk of local reactions means caution may be appropriate, and avoiding contact with the surrounding skin and mucous membranes is important.

Q: Can Locetar be used on fingernails and toenails?

A: Yes, regulatory documents indicate Locetar is intended for the treatment of fungal infections of both fingernails and toenails. The recommended treatment duration differs, typically being approximately six months for fingernails and nine to twelve months for toenails.

Q: What precautions should be taken when applying Locetar in a poorly ventilated room?

A: Official guidance states that because the product is flammable, it should be kept away from heat, open flames, or any other ignition source, including lit cigarettes, until it is completely dry.

Q: Does Locetar contain steroids or hormones?

A: Studies and official information indicate that Locetar does not contain any steroids or hormones. The active ingredient is amorolfine, which is a topical antifungal agent belonging to the morpholine chemical class.

Q: Can Locetar be used for conditions other than fungal nail infections?

A: The 5% medicated nail lacquer formulation is authorized solely for the treatment of fungal infections of the nail (onychomycosis), according to regulatory documents. It is not intended for the treatment of other conditions.

Q: Is Locetar available without a prescription in some countries?

A: Regulatory documents state that the status of amorolfine 5% nail lacquer varies by country. While it is a prescription product in many regions, it can be purchased without a prescription in certain other jurisdictions for the treatment of mild infections.

Q: Does Locetar have a generic version available?

A: Yes, the active ingredient is amorolfine, and generic versions of the 5% medicated nail lacquer are available in various regions under different trade names.

Q: What parts of the body should Locetar absolutely not touch?

A: Regulatory documents state that contact of the medicated nail lacquer with the eyes, ears, and mucous membranes (such as the nose or mouth) is to be avoided.

Q: What happens if a child accidentally touches or swallows Locetar?

A: Official product information states that in the event of accidental oral ingestion, no systemic signs of overdose are expected due to the low absorption of the active ingredient. However, obtaining medical advice is necessary, and appropriate symptomatic measures may be taken.

Q: Are there any specific cleaning methods for the application tools that come with Locetar?

A: According to the instructions for use, the reusable spatula must be cleaned using the provided cleansing pad, which contains an alcohol solution. The regulatory instructions specify not wiping the spatula on the neck of the bottle before storing it.

Q: Can exposure to water or soap reduce the effectiveness of Locetar?

A: The lacquer is designed to be water-resistant once dry. Regulatory documents advise users to wait until the lacquer is fully dry after application before washing their hands, especially if the treatment is applied to fingernails.

Q: How long after using Locetar can a person go swimming or take a shower?

A: The official instructions for use state that the medicated nail lacquer should be allowed to dry for approximately 3 to 5 minutes after application. Once the lacquer is set and dry, exposure to water from showering or swimming is generally acceptable.

How should Locetar be stored and disposed of?

How to Store and Dispose of Locetar (Amorolfine)

Locetar medicated nail lacquer must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.


Storage Requirements

  • Temperature and Protection: The product must be stored at a temperature below 30°C (86°F) and kept away from heat. It is classified as flammable and must not be used or stored near an open flame or any ignition source.
  • Container Integrity: The bottle must be kept tightly closed after every use to prevent evaporation and maintain the solution's quality.
  • Child Safety: This medicine must be stored out of the sight and reach of children.
  • Stability: Do not use the medicine past the expiry date printed on the packaging.

Disposal Instructions

Official regulations require that unused or expired Locetar and its accessories must not be thrown away in household waste or flushed down the drain. The medicine must be disposed of via a proper pharmaceutical waste collection point; consultation with a pharmacist is required to follow correct environmental protection procedures. The used swab is also inflammable and requires careful disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Locetar found in:

A-Z Index: